HPV and Cervical Screening The Facts: A Health Promotion Initiative

Cervical Cancer is the most common malignancy affecting women aged 20-24, with approximately 3,400 cases being diagnosed annually in the UK (Bomford and Knunkler 2003). The aetiological factors associated with cervical cancer are relatively unknown, however scientific evidence links persistent infection with human papilomavirus (HPV) and the development of cervical carcinomas. Research by the PHA found that 50% of sexually active women become infected by genital HPV at least once in their life. There are over 40 different types of HPV that can effect the genital epithelium. Of these types 70% of cases originate from HPV 16 and 18.In 2008 the HPV vaccine programme Cervarix was implemented, offering up to 70% protection against cervical malignancies caused by HPV 16 and 18. Following this the Northern Ireland Cervical Screening Programme introduced a policy change, increasing the target age from 20 to 25 years old. However research has identified limitations in the vaccines long term immunity and its effectiveness in providing adequate protection against other strains of HPV. Therefore the question arises are young women aware of the role of continual cervical screening post HPV vaccination.To increase awareness of the importance of cervical screening post HPV vaccination in adolescent women .To determine current knowledge young women have regarding the importance of cervical screening post HPV vaccination To improve health education and increase Cervical Cancer prevention To improve attendance at cervical screening